Overview of GHK-Cu: A Copper-Binding Peptide for Research

GHK-Cu is a tripeptide with the sequence Gly-His-Lys, complexed with copper(II) ions, possessing a molecular weight of approximately 340.8 Da (free peptide: 262.3 Da; copper-bound: ~340.8 Da). Synthesized for research, it is supplied as a lyophilized powder (typically 50 mg vials, >98% purity) for reconstitution with bacteriostatic water, suitable for in vitro or in vivo studies via topical, subcutaneous, or intravenous administration PMC, GHK-Cu Skin Repair. Naturally present in human plasma at ~200 ng/mL in youth, its levels decline with age, prompting research into its regenerative properties PMC, GHK-Cu Aging.

Developed following discoveries by Dr. Loren Pickart, GHK-Cu is investigated for its ability to regulate fibroblast function, collagen synthesis, and oxidative stress, making it a key tool for studying skin repair, wound healing, and cellular senescence. Its copper-binding affinity enhances its bioactivity, distinguishing it from non-copper-bound GHK. The following sections detail its mechanisms and research applications, emphasizing its role as a research-only compound.

Mechanism of Action: Modulation of Tissue Repair and Cellular Homeostasis

GHK-Cu exerts its effects by interacting with cellular pathways involved in ECM remodeling, angiogenesis, and antioxidant defense, characterized in preclinical models and limited human studies PMC, GHK-Cu Skin Repair.

• Fibroblast Activation and ECM Synthesis: GHK-Cu upregulates collagen, elastin, and glycosaminoglycan production by 50–70% in fibroblast cultures, mediated by transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) signaling PMC, GHK-Cu Aging.

• Angiogenesis Promotion: It enhances VEGF expression, increasing blood vessel formation by 20–30% in rodent wound models, supporting tissue regeneration PMC, GHK-Cu Wound Healing.

• Antioxidant and Anti-Inflammatory Effects: GHK-Cu reduces reactive oxygen species (ROS) by 15–25% and downregulates pro-inflammatory cytokines (e.g., TNF-α, IL-6) by 20%, protecting cells from oxidative stress PMC, GHK-Cu Skin Repair.

• Gene Expression Modulation: It influences over 4,000 genes, upregulating DNA repair (e.g., p53, SIRT1) and tissue remodeling genes by 10–20%, while suppressing senescence markers PMC, GHK-Cu Aging.

• Pharmacokinetics: In preclinical models, GHK-Cu (0.1–10 mg/kg) achieves rapid tissue distribution post-injection, with a half-life of ~1 hour, requiring repeated dosing for sustained effects PMC, GHK-Cu Wound Healing.

Preclinical studies in rats (1 mg/kg/day) showed a 30% faster wound closure and 50% increased collagen deposition, while in vitro data confirmed a 70% boost in fibroblast collagen synthesis PMC, GHK-Cu Skin Repair. Limited human studies (topical 0.01–2% GHK-Cu) suggest enhanced skin remodeling, but data is preliminary PMC, GHK-Cu Aging.

Research Applications of GHK-Cu: Insights from Preclinical and Clinical Studies

GHK-Cu’s multifaceted effects make it a versatile compound for investigating tissue repair and cellular aging. The following applications are strictly for research purposes in controlled environments, supported by peer-reviewed findings:

Skin Repair and ECM Remodeling

GHK-Cu is extensively studied for its effects on skin fibroblasts and wound healing:

• A 50–70% increase in collagen and elastin production in human fibroblast cultures, enhancing ECM integrity PMC, GHK-Cu Skin Repair.

• 30% faster wound closure in rodent skin models (1 mg/kg/day), driven by angiogenesis and fibroblast activation PMC, GHK-Cu Wound Healing.

• Preliminary human data (topical 0.01% GHK-Cu) showed 20% improved skin texture in small trials, requiring further validation PMC, GHK-Cu Aging.

Anti-Aging and Cellular Senescence

GHK-Cu serves as a model for studying cellular aging:

• A 20–25% reduction in senescence markers (p16, p21) in aged fibroblast cultures, restoring proliferative capacity PMC, GHK-Cu Aging.

• Upregulation of SIRT1 and DNA repair genes by 15–20%, supporting longevity pathways in vitro PMC, GHK-Cu Skin Repair.

• Enhanced antioxidant enzyme activity (e.g., superoxide dismutase) by 25%, reducing oxidative damage in cell models PMC, GHK-Cu Wound Healing.

Angiogenesis and Tissue Regeneration

GHK-Cu’s angiogenic properties support tissue repair research:

• A 20–30% increase in blood vessel density in rodent wound models, linked to VEGF upregulation PMC, GHK-Cu Wound Healing.

• Enhanced tissue regeneration in muscle and skin models, with 15–20% improved tensile strength PMC, GHK-Cu Skin Repair.

• Potential to study vascular remodeling, though human data is limited PMC, GHK-Cu Aging.

Neurological Research Potential

Emerging preclinical data suggest GHK-Cu may influence neuroprotective pathways:

• A 10–15% reduction in oxidative stress in neuronal cell cultures, potentially via ROS scavenging PMC, GHK-Cu Skin Repair.

• No direct evidence of cognitive effects, with further research needed to validate neurological applications PMC, GHK-Cu Aging.

These applications are confined to research settings, with no approved therapeutic use in humans.

Research Populations and Study Designs

GHK-Cu’s research applications target specific investigational populations and study designs:

• Preclinical Researchers: Scientists studying fibroblast biology, wound healing, or cellular senescence use GHK-Cu in cell cultures and rodent models PMC, GHK-Cu Skin Repair.

• Regenerative Biology Investigators: Researchers examining angiogenesis or ECM remodeling employ GHK-Cu in tissue repair models PMC, GHK-Cu Wound Healing.

• Aging and Gerontology Scientists: Those investigating senescence or antioxidant pathways use GHK-Cu to study SIRT1 and p53 regulation PMC, GHK-Cu Aging.

Typical study designs involve:

• In Vitro: Fibroblast or neuronal cultures treated with 0.1–10 µM GHK-Cu for 24–72 hours, measuring collagen, VEGF, or senescence markers.

• In Vivo: Rodents dosed at 0.1–10 mg/kg/day (topical or injectable) for 7–28 days, assessing wound closure, angiogenesis, or ECM production.

• Human Studies (Limited): Small trials used topical 0.01–2% GHK-Cu for 4–12 weeks, evaluating skin parameters PMC, GHK-Cu Aging.

Research Limitations and Risks

Several limitations and considerations apply to GHK-Cu research:

• Limited Clinical Data: Human studies are small and preliminary, with no phase 3 trials confirming efficacy or long-term safety PMC, GHK-Cu Aging.

• Regulatory Status: GHK-Cu is not approved by the FDA or any regulatory body for human use and is designated for research purposes only PMC, GHK-Cu Skin Repair.

• Side Effect Profile: Preclinical studies report no significant adverse effects at 0.1–10 mg/kg/day. Limited human trials noted mild skin irritation in <2% of topical users PMC, GHK-Cu Wound Healing.

• Dosing Variability: Research doses (0.1–10 µM in vitro, 0.1–10 mg/kg/day in vivo) lack standardization, requiring precise protocols PMC, GHK-Cu Skin Repair.

• Theoretical Risks: Excessive angiogenesis could theoretically amplify unintended tissue responses, though no evidence supports this at research doses PMC, GHK-Cu Aging.

Conclusion: A Versatile Tool for Regenerative Research

GHK-Cu, a copper-binding tripeptide, offers significant potential as a research tool for studying tissue repair, ECM remodeling, and cellular aging. Preclinical studies demonstrate a 50–70% increase in collagen synthesis, 30% faster wound closure, and 20–25% reduction in senescence markers, while limited human data provide preliminary insights. For researchers investigating regenerative biology, angiogenesis, or anti-aging pathways, GHK-Cu is a precise instrument for controlled studies. Its investigational status, limited clinical data, and regulatory restrictions confine its use to laboratory research.

Key Citations

• GHK-Cu skin repair and ECM remodeling

• GHK-Cu aging and senescence

• GHK-Cu wound healing and angiogenesis

Legal Disclaimer:

The information provided in this article is for research purposes only. GHK-Cu is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of GHK-Cu in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving GHK-Cu.

Additional information

Weight1 lbsDimensions1 × 1 × 1 in

COA

Overview of GHK-Cu: A Copper-Binding Peptide for Research

GHK-Cu is a tripeptide with the sequence Gly-His-Lys, complexed with copper(II) ions, possessing a molecular weight of approximately 340.8 Da (free peptide: 262.3 Da; copper-bound: ~340.8 Da). Synthesized for research, it is supplied as a lyophilized powder (typically 50 mg vials, >98% purity) for reconstitution with bacteriostatic water, suitable for in vitro or in vivo studies via topical, subcutaneous, or intravenous administration PMC, GHK-Cu Skin Repair. Naturally present in human plasma at ~200 ng/mL in youth, its levels decline with age, prompting research into its regenerative properties PMC, GHK-Cu Aging.

Developed following discoveries by Dr. Loren Pickart, GHK-Cu is investigated for its ability to regulate fibroblast function, collagen synthesis, and oxidative stress, making it a key tool for studying skin repair, wound healing, and cellular senescence. Its copper-binding affinity enhances its bioactivity, distinguishing it from non-copper-bound GHK. The following sections detail its mechanisms and research applications, emphasizing its role as a research-only compound.

Mechanism of Action: Modulation of Tissue Repair and Cellular Homeostasis

GHK-Cu exerts its effects by interacting with cellular pathways involved in ECM remodeling, angiogenesis, and antioxidant defense, characterized in preclinical models and limited human studies PMC, GHK-Cu Skin Repair.

• Fibroblast Activation and ECM Synthesis: GHK-Cu upregulates collagen, elastin, and glycosaminoglycan production by 50–70% in fibroblast cultures, mediated by transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) signaling PMC, GHK-Cu Aging.

• Angiogenesis Promotion: It enhances VEGF expression, increasing blood vessel formation by 20–30% in rodent wound models, supporting tissue regeneration PMC, GHK-Cu Wound Healing.

• Antioxidant and Anti-Inflammatory Effects: GHK-Cu reduces reactive oxygen species (ROS) by 15–25% and downregulates pro-inflammatory cytokines (e.g., TNF-α, IL-6) by 20%, protecting cells from oxidative stress PMC, GHK-Cu Skin Repair.

• Gene Expression Modulation: It influences over 4,000 genes, upregulating DNA repair (e.g., p53, SIRT1) and tissue remodeling genes by 10–20%, while suppressing senescence markers PMC, GHK-Cu Aging.

• Pharmacokinetics: In preclinical models, GHK-Cu (0.1–10 mg/kg) achieves rapid tissue distribution post-injection, with a half-life of ~1 hour, requiring repeated dosing for sustained effects PMC, GHK-Cu Wound Healing.

Preclinical studies in rats (1 mg/kg/day) showed a 30% faster wound closure and 50% increased collagen deposition, while in vitro data confirmed a 70% boost in fibroblast collagen synthesis PMC, GHK-Cu Skin Repair. Limited human studies (topical 0.01–2% GHK-Cu) suggest enhanced skin remodeling, but data is preliminary PMC, GHK-Cu Aging.

Research Applications of GHK-Cu: Insights from Preclinical and Clinical Studies

GHK-Cu’s multifaceted effects make it a versatile compound for investigating tissue repair and cellular aging. The following applications are strictly for research purposes in controlled environments, supported by peer-reviewed findings:

Skin Repair and ECM Remodeling

GHK-Cu is extensively studied for its effects on skin fibroblasts and wound healing:

• A 50–70% increase in collagen and elastin production in human fibroblast cultures, enhancing ECM integrity PMC, GHK-Cu Skin Repair.

• 30% faster wound closure in rodent skin models (1 mg/kg/day), driven by angiogenesis and fibroblast activation PMC, GHK-Cu Wound Healing.

• Preliminary human data (topical 0.01% GHK-Cu) showed 20% improved skin texture in small trials, requiring further validation PMC, GHK-Cu Aging.

Anti-Aging and Cellular Senescence

GHK-Cu serves as a model for studying cellular aging:

• A 20–25% reduction in senescence markers (p16, p21) in aged fibroblast cultures, restoring proliferative capacity PMC, GHK-Cu Aging.

• Upregulation of SIRT1 and DNA repair genes by 15–20%, supporting longevity pathways in vitro PMC, GHK-Cu Skin Repair.

• Enhanced antioxidant enzyme activity (e.g., superoxide dismutase) by 25%, reducing oxidative damage in cell models PMC, GHK-Cu Wound Healing.

Angiogenesis and Tissue Regeneration

GHK-Cu’s angiogenic properties support tissue repair research:

• A 20–30% increase in blood vessel density in rodent wound models, linked to VEGF upregulation PMC, GHK-Cu Wound Healing.

• Enhanced tissue regeneration in muscle and skin models, with 15–20% improved tensile strength PMC, GHK-Cu Skin Repair.

• Potential to study vascular remodeling, though human data is limited PMC, GHK-Cu Aging.

Neurological Research Potential

Emerging preclinical data suggest GHK-Cu may influence neuroprotective pathways:

• A 10–15% reduction in oxidative stress in neuronal cell cultures, potentially via ROS scavenging PMC, GHK-Cu Skin Repair.

• No direct evidence of cognitive effects, with further research needed to validate neurological applications PMC, GHK-Cu Aging.

These applications are confined to research settings, with no approved therapeutic use in humans.

Research Populations and Study Designs

GHK-Cu’s research applications target specific investigational populations and study designs:

• Preclinical Researchers: Scientists studying fibroblast biology, wound healing, or cellular senescence use GHK-Cu in cell cultures and rodent models PMC, GHK-Cu Skin Repair.

• Regenerative Biology Investigators: Researchers examining angiogenesis or ECM remodeling employ GHK-Cu in tissue repair models PMC, GHK-Cu Wound Healing.

• Aging and Gerontology Scientists: Those investigating senescence or antioxidant pathways use GHK-Cu to study SIRT1 and p53 regulation PMC, GHK-Cu Aging.

Typical study designs involve:

• In Vitro: Fibroblast or neuronal cultures treated with 0.1–10 µM GHK-Cu for 24–72 hours, measuring collagen, VEGF, or senescence markers.

• In Vivo: Rodents dosed at 0.1–10 mg/kg/day (topical or injectable) for 7–28 days, assessing wound closure, angiogenesis, or ECM production.

• Human Studies (Limited): Small trials used topical 0.01–2% GHK-Cu for 4–12 weeks, evaluating skin parameters PMC, GHK-Cu Aging.

Research Limitations and Risks

Several limitations and considerations apply to GHK-Cu research:

• Limited Clinical Data: Human studies are small and preliminary, with no phase 3 trials confirming efficacy or long-term safety PMC, GHK-Cu Aging.

• Regulatory Status: GHK-Cu is not approved by the FDA or any regulatory body for human use and is designated for research purposes only PMC, GHK-Cu Skin Repair.

• Side Effect Profile: Preclinical studies report no significant adverse effects at 0.1–10 mg/kg/day. Limited human trials noted mild skin irritation in <2% of topical users PMC, GHK-Cu Wound Healing.

• Dosing Variability: Research doses (0.1–10 µM in vitro, 0.1–10 mg/kg/day in vivo) lack standardization, requiring precise protocols PMC, GHK-Cu Skin Repair.

• Theoretical Risks: Excessive angiogenesis could theoretically amplify unintended tissue responses, though no evidence supports this at research doses PMC, GHK-Cu Aging.

Conclusion: A Versatile Tool for Regenerative Research

GHK-Cu, a copper-binding tripeptide, offers significant potential as a research tool for studying tissue repair, ECM remodeling, and cellular aging. Preclinical studies demonstrate a 50–70% increase in collagen synthesis, 30% faster wound closure, and 20–25% reduction in senescence markers, while limited human data provide preliminary insights. For researchers investigating regenerative biology, angiogenesis, or anti-aging pathways, GHK-Cu is a precise instrument for controlled studies. Its investigational status, limited clinical data, and regulatory restrictions confine its use to laboratory research.

Key Citations

• GHK-Cu skin repair and ECM remodeling

• GHK-Cu aging and senescence

• GHK-Cu wound healing and angiogenesis

Legal Disclaimer:

The information provided in this article is for research purposes only. GHK-Cu is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of GHK-Cu in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving GHK-Cu.